Meeting NewsVideo

VIDEO: Improvements maintained for 2 years with abicipar for wet AMD

SAN FRANCISCO — Rahul Khurana, MD, of Northern California Retina Vitreous Associates, shared the 2-year results from the CEDAR and SEQUOIA studies, which showed abicipar given every 12 weeks and every 8 weeks was equivalent to ranibizumab every 4 weeks for neovascular age-related macular degeneration at the American Academy of Ophthalmology annual meeting.

“The impressive aspect of the study was the visual gains seen in the first years were maintained with only four treatments in the abicipar every 12-week arm,” he said. “There were improvements in visual acuity and the retinal thickness were maintained through 2-year study trial.”

Disclosure: Khurana reports consulting for and receiving grant support from Allergan.

SAN FRANCISCO — Rahul Khurana, MD, of Northern California Retina Vitreous Associates, shared the 2-year results from the CEDAR and SEQUOIA studies, which showed abicipar given every 12 weeks and every 8 weeks was equivalent to ranibizumab every 4 weeks for neovascular age-related macular degeneration at the American Academy of Ophthalmology annual meeting.

“The impressive aspect of the study was the visual gains seen in the first years were maintained with only four treatments in the abicipar every 12-week arm,” he said. “There were improvements in visual acuity and the retinal thickness were maintained through 2-year study trial.”

Disclosure: Khurana reports consulting for and receiving grant support from Allergan.

    See more from Discoveries from AAO: AMD